- About us
- About Vaccines
- Media centre
- Become a member
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Vaccines Europe welcomes the EU Health Council adoption of the Council Conclusions on the next steps under a one health approach to combat antimicrobial resistance. Vaccines Europe believes that a holistic approach that takes into account alternative approaches which can reduce the use of antibiotics should be considered as part of a long term strategy to combat this global public health issue. The Council Conclusions call upon the Member States to “encourage the use of alternative treatment and prevention options including vaccines and the development and use of affordable diagnostics tests in human and veterinary medicine“, which is in line with recent evidence that suggests that antibiotic use can decrease in association with the initiation of immunisation programmes or increased uptake of available vaccines. The Vaccines Europe members are committed to this global health issue by investing in the development of vaccines that target resistant bacteria that causes healthcare associated infections, such as Staphylococcus aureus and Clostridium difficile which would play a crucial role in tackling drug resistance.
Find here a draft Vaccines Europe paper on the Role of vaccination in reducing antimicrobial resistance.
Europe has been a long-standing leader in vaccines. Maintaining this position and ensuring vaccine availability in times of increased demand and supply constraints can only be achieved by a strong industry operating in a stable environment, able to produce vaccines of the highest quality and to innovate to meet future vaccine needs.
In the light of achieving these goals, Vaccines Europe issued a position paper on the topic of vaccine shortages, which can be accessed on this link.